MUC1 expression in hematopoietic tissues

American Journal of Clinical Pathology

Volumn 111, Issue 6, 1999, Pages 741-747

  Dent, Georgette A ^a   Civalier, Chris J ^a   Brecher, Mark E ^a   Bentley, Stuart A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Bone marrow; Breast cancer; Lymph node; MUC1

Indexed keywords

EPISIALIN; MUCIN; RNA; UNCLASSIFIED DRUG;

ARTICLE; BLOOD; BONE MARROW; BREAST CANCER; CONTROLLED STUDY; GRANULOCYTE; HEMATOPOIETIC TISSUE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; LYMPH NODE; LYMPH NODE METASTASIS; LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0033004971     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/111.6.741     Document Type: Article

References (35)

1. Hutter RVP. The role of the pathologist in breast cancer management. Cancer. 1990;66:1363-1372.
2. Fisher B, Bauer M, Wickerham DL, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer: an NSABP update. Cancer. 1983;52:1551-1557.
3. McGuire WL. Prognostic factors for recurrence and survival in human breast cancer. Breast Cancer Res Treat. 1987;10:5-9.
4. Fisher ER, Redmond C, Fisher B. Prognostic factors in NSABP studies of women with node-negative breast cancer. J Natl Cancer Inst Monogr. 1992;11:151-158.
5. Friedman S, Bertin F, Mouriesse H, et al. Importance of tumor cells in axillary node sinus margins ("clandestine" metastases) discovered by serial sectioning in operable breast carcinoma. Acta Oncol. 1988;27:483-487.
6. Wilkinson EJ, Hause LL, Hoffman RG, et al. Occult axillary lymph node metastases in invasive breast carcinoma: characteristics of the primary tumor and significance of the metastases. Pathol Annu. 1982;17:67-91.
7. de Mascarel I, Bonichon F, Coindre JM, et al. Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up. Br J Cancer. 1992;66:523-527.
8. Wells CA, Heryet A, Brochier J, et al. The immunocytochemical detection of axillary micrometastases in breast cancer. Br J Cancer. 1984;50:193-197.
9. Noguchi S, Aihara T, Nakamori S, et al. The detection of breast carcinoma micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Cancer. 1994;74:1595-1600.
10. Noguchi S, Aihara T, Motomura K, et al. Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Am J Pathol. 1996;148:649-656.
11. Schoenfeld A, Luqmani Y, Smith D, et al. Detection of breast cancer micrometastases in axillary lymph nodes by using polymerase chain reaction. Cancer Res. 1994;54:2986-2990.
12. Ligtenberg MJL, Vos HL, Gennissen AMC, et al. Episialin, a carcinoma-associated mucin, is generated by a polymorphic gene encoding splice variants with alternative amino termini. J Biol Chem. 1990;265:5573-5578.
13. Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, et al. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem. 1990;265:15286-15293.
14. Gum JR, Hicks JW, Swallow DM, et al. Molecular cloning of cDNAs derived from a novel human intestinal mucin gene. Biochem Biophys Res Commun. 1990;171:407-415.
15. Swallow DM, Gendler S, Griffiths B, et al. The hypervariable gene locus PUM, which codes for the tumor-associated epithelial mucins, is located on chromosome 1, within the region q21-24-Ann Hum Genet. 1987;51:289-294.
16. Lancaster CA, Peat N, Duhig T, et al. Structure and expression of the human polymorphic epithelial mucin gene: an expressed VNTR unit. Biochem Biophys Res Commun. 1990;173:1019-1029.
17. Oka K, Hoshi T, Nakano T, et al. Expression of human milk fat globule-1 in carcinomas of the uterine cervix treated with radiation therapy alone. Arch Pathol Lab Med. 1992;116:955-959.
18. Lan MS, Batra SK, Qi W-N, et al. Cloning and sequencing of a human pancreatic tumor mucin cDNA. J Biol Chem. 1990;265:15294-15299.
19. Ho SB, Niehans GA, Lyftogt C, et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res. 1993;53:641-651.
20. Zotter S, Hageman PC, Lossnitzer A, et al. Tissue and tumor distribution of human polymorphic epithelial mucin. Cancer Rev. 1988;11:55-101.
21. Hilkens J, Buijs F, Hilgers J, et al. Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int J Cancer. 1984;34:197-206.
22. Gum JR. Mucin genes and the proteins they encode: structure, diversity, and regulation. Am J Respir Cell Mol Biol. 1992;7:557-564.
23. Heyderman E, Strudley I, Powell G, et al. A new monoclonal antibody to epithelial membrane antigen (EMA)-E29: a comparison of its immunocytochemical reactivity with polyclonal anti-EMA antibodies and with another monoclonal antibody, HMFG-2. Br J Cancer. 1985;52:355-361.
24. Cordell J, Richardson TC, Pulford KAF, et al. Production of monoclonal antibodies against human epithelial membrane antigen for use in diagnostic immunocytochemistry. Br J Cancer. 1985;52:347-354.
25. Hilkens J, Vos HL, Wesseling J, et al. Is episialin/MUC1 involved in breast cancer progression? Cancer Lett. 1995;90:27-33.
26. Wesseling J, van der Valk SW, Vos HL, et al. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol. 1995;129:255-265.
27. Ligtenberg MJL, Buijs F, Vos HL, et al. Suppression of cellular aggregation by high levels of episialin. Cancer Res. 1992;52:2318-2324.
28. Pinkus GS, Kurtin PJ. Epithelial membrane antigen: a diagnostic discriminant in surgical pathology: immunohistochemical profile in epithelial, mesenchymal, and hematopoietic neoplasms using paraffin section and monoclonal antibodies. Hum Pathol. 1985; 16:929-940.
29. Vizcarra E, Lluch A, Cibrian R, et al. CA 15.3, CEA, and TPA tumor markers in the early diagnosis of breast cancer relapse. Oncology. 1994;51:491-496.
30. Berruti A, Tampellini M, Torta M, et al. Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease. Eur J Cancer. 1994;30A:2082-2084.
31. Cohen AD, Gopas J, Karplus G, et al. CA 15-3, mucin-like carcinoma-associated antigen and tissue polypeptide-specific antigen: correlation to disease state and prognosis in breast cancer patients. Isr J Med Sci. 1995;31:155-159.
32. Ben-Ezra J, Johnson DA, Rossi J, et al. Effect of fixation on the amplification of nucleic acids from paraffin-embedded material by the polymerase chain reaction. J Histochem Cytochem. 1991;39:351-354.
33. Hoon DSB, Doi F, Giuliano AE. The detection of breast carcinoma micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Cancer. 1995;76:533-535.
34. Ng S-Y, Gunning P, Eddy R, et al. Evolution of the functional human p-actin gene and its multi-pseudogene family: conservation of noncoding regions and chromosomal dispersion of pseudogenes. Mol Cell Bid. 1985;5:2720-2732.
35. Dearnaley DP, Sloane JP, Imrie S, et al. Detection of isolated mammary carcinoma in marrow of patients with primary breast cancer. J R Soc Med. 1983;76:359-364.